eFoodSafety.com, Inc. Announces Groundbreaking Laboratory Test Results Against Tuberculosis with its Trimycin Product.

Test results demonstrated killing the Tuberculosis organism while remaining non-toxic to normal cells

SCOTTSDALE, Ariz. -- eFoodSafety.com, Inc. (OTCBB:EFSF), dedicated to improving health conditions around the world through innovative products and technologies, today announced that the Company received positive laboratory test results on the eradication of Tuberculosis organism (Mycobacterium Tuberculosis) with the use of its patent-pending product Trimycin. The testing was conducted by the National Center for Genetic Engineering and Biotechnology (BIOTEC), a branch of the National Science and Technology Development Agency (NSTDA) located in the greater Bangkok metropolitan area of Thailand.

Testing consisted of using live tissue samples inoculated with Mycobacterium Tuberculosis exposed to various concentrations of Trimycin. The test results demonstrated that Trimycin killed the Tuberculosis organism while remaining non-toxic to normal cells. The ability of Trimycin to eradicate the Tuberculosis organisms within the cells without affecting the normal cells is of major impact in the treatment of Tuberculosis (TB).

According to Global Health Reporting.org, more than 8 million people develop active TB annually, and approximately two million die from the disease each year. Of the estimated 8.9 million cases worldwide, over 700,000 were also HIV-positive. In 2004, 1.7 million people died of TB and fifteen percent (15%) of those who died were also infected with HIV. Global access to TB treatment remains low and very expensive. The Company feels that this is where Trimycin could have a major impact on the treatment of TB.

"We are now able to progress to live subjects to continue our testing on this groundbreaking discovery of Trimycin's effect on TB. We believe eFoodSafety is well positioned in the treatment of this deadly disease and we hope to make a major contribution to the world in the treatment of deadly infectious diseases," stated Mr. Robert Bowker, President and CEO of Knock-Out Technologies, Ltd., a wholly-owned subsidiary of eFoodSafety.com, Inc., and formulator of the patent-pending Trimycin product.

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn[TM]-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn[TM] line. The company is also a distributor for Cinnergen[TM], a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous[TM], a weight loss formula focusing on the body's 24-hour metabolic processes. The company has recently entered into a joint venture agreement with CK41 Direct, Inc. to launch an anti-acne skin care system, with a branded name and celebrity spokesperson to be announced in the near future.

Please visit the Company's website at: http://www.efoodsafety.com.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.